Age related Macular Degeneration (AMD)

Advanced Research in Wet AMD Treatment: Exploring Patient Experiences, Treatment Efficacy, and Risk Factors

Our research group is deeply committed to advancing the field of neovascular age-related macular degeneration (AMD) treatment. Through extensive registry research, we focus on the application of intravitreal VEGF (vascular endothelial growth factor) inhibitor therapy as the primary approach to treating neovascular AMD. Additionally, we investigate potential risk factors associated with the use of VEGF-inhibitor therapy.

Emphasis on Patient Experiences and Result Utilization

We attempt to comprehend the patient perspective and their experiences with neovascular AMD treatment. Through interviews and questionnaire surveys, we explore patients' reactions to treatment and their overall visual function and quality of life. This provides invaluable insights into how our research findings can be integrated into patients' treatment journeys and enhance their quality of life.